Article(electronic)#12004
Primärtherapie des Ovarialkarzinoms
In: Zentralblatt für Gynäkologie, Volume 126, Issue 5, p. 312-314
ISSN: 1438-9762
Search results
Filter
6 results
Sort by:
Checking availability at your location
This article is also available at your library: |
electronic
print
Article(electronic)#2February 9, 2005
Das Qualitätssicherungsprogramm der AGO Organkommission OVAR (QS-OVAR): Versorgungsstruktur und Realität in Deutschland 2001
In: Zentralblatt für Gynäkologie, Volume 127, Issue 1, p. 9-17
ISSN: 1438-9762
Checking availability at your location
This article is also available at your library: |
electronic
print
Article(electronic)#3February 9, 2005
Welchen Einfluss haben Klinikmerkmale auf die Prognose beim Ovarialkarzinom in Deutschland?
In: Zentralblatt für Gynäkologie, Volume 127, Issue 1, p. 18-30
ISSN: 1438-9762
Checking availability at your location
This article is also available at your library: |
electronic
print
Article(electronic)#4August 2006
Ovarialkarzinom - ist die intraperitoneale Therapie wirklich neuer Standard?
In: Zentralblatt für Gynäkologie, Volume 128, Issue 4, p. 202-206
ISSN: 1438-9762
Checking availability at your location
This article is also available at your library: |
electronic
print
Article(electronic)#5February 2006
Diagnostik und Therapie maligner Ovarialtumoren 2005: Die Empfehlungen der Kommission Ovar der AGO
In: Zentralblatt für Gynäkologie, Volume 128, Issue 1, p. 11-17
Schmalfeldt, B.; du Bois, A.; Burges, A.; Emons, G.; Fink, D.; Gropp, M.; Hasenburg, A.; Jäger, W.; Kimmig, R.; Kiechle, M.; Kommoss, F.; Kreienberg, R.; Kuhn, W.; Lück, H.-J.; Meier, W.; Münstedt, K.; Ortmann, O.; Pfisterer, J.; Richter, B.; Runnebaum, I.; Schröder, W.; Sehouli, J.; Tanner, B.; Wagner, U.; Weis, J.
ISSN: 1438-9762
Checking availability at your location
This article is also available at your library: |
electronic
print
Open Access#62017
Harmonising clinical trials within the Gynecologic Cancer InterGroup: Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference
Bookman, M. A; Okamoto, A; Stuart, G; Yanaihara, N; Aoki, D; Bacon, M; Fujiwara, K; González-Martín, A
Bookman, M. A; Okamoto, A; Stuart, G; Yanaihara, N; Aoki, D; Bacon, M; Fujiwara, K; González-Martín, A; Harter, P; Kim, J. W; Ledermann, J; Pujade-Lauraine, E; Quinn, M; Ochiai, K; Zeimet, A; Marth, C; Dubois, Alain; Hilpert, F; Pfisterer, J; Reuss, A; Friedlander, M; Wilson, M. K; Kridelka, Frédéric; Vergote, I; Berek, J; Dorigo, O; Karam, A; Bekkers, R; Westermann, A; Gatsonis, C; Ng, C; Herráez, A. C; Ottevanger, N; Poveda, A; Redondo, A; Coleman, R; Lu, K; Gallardo-Rincón, D; Gomez-Garcia, E; Joly, F; Leary, A; Ray-Coquard, I; Burger, R; Moore, K. N; Fujiwara, H; Hasegawa, K; Gleeson, N; Levy, T; Rosengarten, O; Katsumata, N; Silverberg, S. G; Sugiyama, T; Chang, S.-J; Kim, B.-G; Nam, B.-H; Colombo, N; Ferrero, A; Lorusso, D; Scambia, G; Edmondson, R; McNeish, I; Kohn, E; Hirte, H; McGee, J; Provencher, D; Sehouli, J; Wimberger, P; Maenpaa, J; Mirza, Mansoor Raza; Oza, A; Welch, S; Gaffney, D; Small, W; Glasspool, R; Gourley, C; Millan, D; Zang, R; Zhu, J
The Gynecologic Cancer InterGroup (GCIG) Fifth Ovarian Cancer Consensus Conference (OCCC) was held in Tokyo, Japan from 7 to 9 November 2015. It provided international consensus on 15 important questions in 4 topic areas, which were generated in accordance with the mission statement to establish 'International Consensus for Designing Better Clinical Trials'. The methodology for obtaining consensus was previously established and followed during the Fifth OCCC. All 29 clinical trial groups of GCIG participated in program development and deliberations. Draft consensus statements were discussed in topic groups as well as in a plenary forum. The final statements were then presented to all 29 member groups for voting and documentation of the level of consensus. Full consensus was obtained for 11 of the 15 statements with 28/29 groups agreeing to 3 statements, and 27/29 groups agreeing to 1 statement. The high acceptance rate of the statements among trial groups reflects the fact that we share common questions, and recognise important unmet needs that will guide future research in ovarian cancer. © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. ; Peer reviewed
BASE